TipRanks (Tue, 10-Mar 6:30 AM ET)
Globe Newswire (Mon, 9-Mar 8:30 AM ET)
Protalix Gains EU Approval for Extended Elfabrio Dosing
TipRanks (Mon, 9-Mar 8:25 AM ET)
Globe Newswire (Mon, 9-Mar 6:00 AM ET)
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
Globe Newswire (Wed, 4-Mar 4:32 PM ET)
Market Chameleon (Mon, 2-Feb 6:09 AM ET)
Market Chameleon (Fri, 30-Jan 6:09 AM ET)
Globe Newswire (Fri, 30-Jan 9:47 AM ET)
Globe Newswire (Fri, 30-Jan 9:47 AM ET)
Protalix BioTherapeutics Letter to Stockholders
PRNewswire (Mon, 5-Jan 6:50 AM ET)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of March 10, 2026, PLX stock price climbed to $2.90 with 622,672 million shares trading.
PLX has a beta of 1.26, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.06 to the broad based SPY ETF.
PLX has a market cap of $233.22 million. This is considered a Small Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $18 million in Revenue and $.03 earnings per share. This fell short of revenue expectation by $-194,300 and missed earnings estimates by -$.02.
In the last 3 years, PLX traded as high as $3.55 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, IWC, EES.
PLX has outperformed the market in the last year with a return of +23.9%, while the SPY ETF gained +18.8%. In the last 3 month period, PLX beat the market returning +65.7%, while SPY returned -0.6%. However, in the most recent 2 weeks PLX has underperformed the stock market by returning -7.6%, while SPY returned -0.8%.
PLX support price is $2.76 and resistance is $3.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.